Volume 17, Number 2—February 2011
Dispatch
Primary Amebic Meningoencephalitis Caused by Naegleria fowleri, Karachi, Pakistan
Table
Characteristic |
Patient nos., in order of treatment |
Descriptive statistics† |
||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
||
Age, y | 31 | 25 | 30 | 36 | 60 | 30 | 64 | 18 | 22 | 16 | 18 | 18 | 35 | Mean 31.0 ± 15.33 |
Date treatment sought | 2008 Jul | 2008 Sep | 2009 Apr | 2009 May | 2009 Jul | 2009 Jul | 2009 Jul | 2009 Jul | 2009 Aug | 2009 Aug | 2009 Oct | 2009 Oct | 2009 Nov | |
Duration of illness before seeking treatment, d | 2 | 1 | 2 | 4 | 4 | 1 | 2 | 5 | 2 | 2 | 2 | 3 | 3 | Mean ± SD 2.5 ± 1.19 |
Duration of survival after symptom onset, d |
6 |
15 |
3 |
6 |
7 |
9 |
7 |
6 |
5 |
3 |
3 |
7 |
6 |
Mean ± SD 6.38 ± 3.15 |
Fever | + | + | + | + | + | + | + | + | + | + | + | + | + | Present in 13/13 (100%) |
Headache | + | + | + | + | + | + | + | – | + | + | + | + | + | Present in 12/13 (92.3%) |
Seizures |
+ |
– |
+ |
– |
+ |
– |
+ |
– |
+ |
+ |
+ |
+ |
– |
Present in 8/13 (61.5%) |
CSF analysis | ||||||||||||||
Glucose, mg/dL† | <5 | 42 | 2 | <5† | 26 | <5† | <5‡ | 30 | <5‡ | <5‡ | 80 | 50 | <5‡ | Undetectable in 53.8% |
Protein, mg/dL | 1,028 | 418 | 909 | 774 | 504 | 1,147 | 1342 | 320 | 998 | 330 | 371 | 179 | 1,296 | Mean ± SD 739.69 ± 405.29 |
Leukocytes, cells/mm3 | 900 | 900 | 5,976 | 2,000 | 2,500 | 7,500 | 5,200 | 6,000 | 840 | 6,500 | 150 | 185 | 11,750 | Mean ± SD 3,877.0 ± 3,565.37 |
Neutrophils, % | 15 | 90 | 90 | 90 | 60 | 80 | 90 | 90 | 90 | 96 | 75 | 25 | 95 | Neutrophilic pleocytosis, 84.6 |
Lymphocytes, % | 85 | 10 | 10 | 10 | 40 | 20 | 10 | 10 | 10 | 4 | 25 | 75 | 5 | Lymphocytic pleocytosis, 15.4 |
CSF amebic culture | NA | + | + | + | + | + | + | + | + | + | + | + | + | NA |
CSF PCR for N. fowleri | NA | NA | NA | NA | + | + | + | NA | NA | NA | NA | NA | NA | NA |
*All patients were male except patient no. 11, who was female. CSF, cerebrospinal fluid; +, present; NA, no data available.
†Statistics derived in SPSS software version 16.0 (LEAD Technologies, Charlotte, NC, USA).
‡Glucose <5 mg/dL= undetectable.
Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.